Fang Sheng Pharmaceutical(603998) announced on the evening of January 25 that its wholly-owned subsidiary, Guangdong Fang Sheng Jian Meng Pharmaceutical Co., Ltd., received a Drug Registration Certificate issued by the National Medical Products Administration on January 23. Loxoprofen sodium gel patch has obtained a drug approval number and can be produced. This drug is suitable for anti-inflammatory and analgesic purposes for osteoarthritis, muscle pain, and post-traumatic swelling and pain.

According to the announcement, loxoprofen sodium gel patch is one of the leading-selling analgesics in the Chinese market. Its active ingredient is a phenylpropionic acid nonsteroidal anti-inflammatory drug (NSAID), which has significant anti-inflammatory and analgesic effects. As of the date of the announcement, the project had accumulated an investment of RMB 7.0366 million. According to data from Moshang Pharmaceuticals, the product's sales in hospitals across all terminals reached RMB 1.349 billion in the first three quarters of 2025, and RMB 1.709 billion for the entire year of 2024.

Currently, 15 companies in China have obtained registration certificates for this drug.

The announcement stated that this approval will further enrich the company's product line of orthopedic drugs and enhance its market competitiveness in this field. The company already has several orthopedic products on the market, including Xuanqi Jian Gu Pian and Teng Huang Jian Gu Pian. According to relevant regulations, the newly approved products do not require further consistency evaluation.